Humana
HUM
$379.22
+2.86%
Humana Inc. is one of the largest private health insurers in the United States, operating within the Medical - Healthcare Plans industry. The company has carved out a distinct competitive identity as a specialist in government-sponsored programs, with nearly all its medical membership derived from Medicare, Medicaid, and the military's Tricare program. The current investor narrative is dominated by the sector's reaction to regulatory updates on Medicare Advantage payments, which significantly impact revenue visibility, alongside the company's ongoing efforts to integrate and expand its healthcare services, including primary care and at-home offerings, to drive long-term growth.…
HUM
Humana
$379.22
Related headlines
Investment Opinion: Should I buy HUM Today?
Rating & Thesis: Hold. The stock presents a high-risk, high-potential-reward scenario where powerful technical momentum and a catalytic regulatory relief are balanced against severe fundamental volatility and valuation that may already reflect the good news. The mixed analyst sentiment, with ratings from Sell to Buy, underscores this lack of clear conviction.
Supporting Evidence: The primary valuation metric, the Price-to-Sales ratio of 0.24, is at a deep historical discount, suggesting significant upside if multiples normalize. Revenue growth remains solid at 11.3% YoY. However, profitability is highly inconsistent, with Q4 showing a net margin of -2.45%. The stock has also massively outperformed the market recently, with a 3-month return of 95.26% versus the S&P 500's 12.6%, indicating the positive catalyst may already be priced in.
Risks & Conditions: The two biggest risks are 1) a failure to translate the Medicare payment boost into sustained profit growth, and 2) a continuation of the extreme quarterly earnings volatility seen in Q4. This Hold rating would upgrade to a Buy if the company demonstrates a return to consistent profitability (e.g., two consecutive quarters of positive net income) and the PS ratio remains below 0.3. It would downgrade to a Sell if quarterly losses persist or the stock fails to hold above the $300 support level on a closing basis. Currently, the stock appears fairly valued relative to its improved regulatory outlook but still-high operational risks.
Sign up to view all
HUM 12-Month Price Forecast
Humana is at an inflection point. The powerful rally from deeply oversold conditions, driven by a key regulatory catalyst, has likely captured the near-term upside. The core investment question has shifted from 'is the worst over?' to 'can profits stabilize?'. The neutral stance reflects the high probability of consolidation (base case) as the market digests the good news and demands proof of execution. Confidence is medium due to the stock's proven volatility and the low analyst coverage clouding the consensus view. The stance would turn bullish on evidence of sustained margin improvement for two quarters; it would turn bearish if the stock breaks below the $300 support level on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana's 12-month outlook, with a consensus price target around $492.99 and implied upside of +30.0% versus the current price.
Average Target
$492.99
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$303 - $493
Analyst target range
Analyst coverage is limited, with only 7 analysts providing estimates, indicating this large-cap stock may have subdued institutional interest following its recent challenges. The consensus sentiment appears mixed, as institutional ratings from February 2026 show a distribution including Sell (Goldman Sachs), Hold/Equal Weight (multiple firms), and Buy (Jefferies, Guggenheim), with no clear directional bias and several firms maintaining neutral stances. The wide dispersion in ratings and the lack of a recent average price target in the data signal high uncertainty and low conviction among analysts, which is consistent with the stock's high volatility and the complex regulatory backdrop; this environment typically leads to less efficient price discovery and requires investors to conduct deep fundamental due diligence independently.
Bulls vs Bears: HUM Investment Factors
The investment debate for Humana is a classic clash between deep value and fundamental instability. The bull case, currently supported by stronger evidence from the powerful price reversal and catalytic regulatory news, hinges on the extreme valuation discount (PS of 0.24) providing a margin of safety for a turnaround. The bear case is grounded in severe and unpredictable earnings volatility, exemplified by the swing from a Q3 profit to a large Q4 loss. The single most important tension is whether the favorable Medicare payment update and management execution can stabilize profitability and justify a higher multiple, or if persistent margin pressure and cash flow issues will validate the stock's discounted valuation as a 'value trap.'
Bullish
- Extreme Valuation Discount: The stock trades at a trailing PS ratio of 0.24, which is exceptionally low for a healthcare plan provider and near the absolute bottom of its historical valuation range. This deep discount suggests the market has priced in a worst-case scenario, creating significant potential for multiple expansion if the company stabilizes its earnings.
- Powerful Technical Reversal: HUM has surged 95.26% over the past three months and is now testing its 52-week high of $351.88, signaling a decisive bullish reversal from its -47.54% drawdown low. The 46.04% gain over the past month, with a relative strength of 41.44 versus the S&P 500, indicates strong, company-specific momentum.
- Regulatory Catalyst for Revenue: Recent news confirms a larger-than-expected 2027 Medicare Advantage payment increase from CMS, which directly boosts revenue visibility for Humana's core business. This positive regulatory development is a primary driver behind the recent sector-wide rally and alleviates a major overhang on the stock.
- Solid Underlying Revenue Growth: Q4 2025 revenue of $32.52 billion represents an 11.3% year-over-year increase, demonstrating the company's ability to grow its top line despite profitability challenges. This consistent revenue growth provides a fundamental base for recovery.
Bearish
- Severe Earnings Volatility & Loss: The company reported a massive Q4 2025 net loss of -$796 million, a sharp reversal from a $195 million profit in Q3. This extreme quarterly volatility, with gross margin contracting from 14.27% to 11.67%, highlights significant and unpredictable margin pressure from medical costs.
- Negative Free Cash Flow in Q4: Despite generating positive TTM free cash flow of $375 million, Q4 2025 alone saw a concerning negative free cash flow of -$1.85 billion. This indicates potential heavy cash outlays or working capital issues in the period, raising questions about near-term financial flexibility.
- Analyst Uncertainty & Low Coverage: Only 7 analysts cover this large-cap stock, and institutional ratings show a wide dispersion from Sell to Buy with no clear consensus. This low coverage and high uncertainty among professionals reflect the complex, high-risk investment narrative and complicate price discovery.
- Tight Liquidity Position: The company's current ratio of 0.72 indicates a tight liquidity position, meaning current assets do not fully cover current liabilities. This financial constraint could limit operational flexibility, especially if quarterly cash burn persists.
HUM Technical Analysis
The stock is in a powerful recovery trend, having surged 95.26% over the past three months and 51.54% over the past year, decisively reversing a steep decline that saw a maximum drawdown of -47.54%. Currently trading at $349.80, the price sits at approximately 99.4% of its 52-week high of $351.88, indicating it is testing a critical resistance level at the peak of its range, which suggests either strong momentum or potential overextension. Recent momentum is exceptionally strong, with a 46.04% gain over the past month, far outpacing the S&P 500's 4.6% rise, as evidenced by a relative strength of 41.44; this acceleration from the longer-term trend signals a powerful bullish reversal following the sharp sell-off in late January. Key technical support is anchored at the 52-week low of $163.11, while immediate resistance is the 52-week high of $351.88; a confirmed breakout above this level would signal a resumption of the long-term uptrend, whereas a failure could lead to consolidation. The stock's beta of 0.68 indicates it is about 32% less volatile than the broader market, which is notable given its recent explosive price moves and suggests the rally has been driven by strong company-specific catalysts rather than broad market risk-on sentiment.
Beta
0.77
0.77x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$379
Price range past year
Annual Return
+61.4%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | +24.4% | -0.1% |
| 3m | +129.2% | +12.0% |
| 6m | +41.3% | +8.8% |
| 1y | +61.4% | +22.9% |
| ytd | +43.4% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth has been solid, with Q4 2025 revenue of $32.52 billion representing an 11.3% year-over-year increase; however, the quarterly trend shows volatility, as revenue sequentially declined from $32.65 billion in Q3, indicating potential lumpiness in premium recognition or membership trends. Profitability has been highly inconsistent, with Q4 2025 showing a net loss of -$796 million and a gross margin of 11.67%, a sharp contraction from the 14.27% gross margin in Q3; this quarterly loss follows a profitable Q3 with net income of $195 million, highlighting significant margin pressure and earnings volatility tied to medical cost trends and potential reserve adjustments. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.73, and while the current ratio of 0.72 indicates tight liquidity, the company generated positive free cash flow of $375 million on a trailing twelve-month basis, suggesting it can fund operations internally; however, the negative free cash flow of -$1.85 billion in Q4 2025 alone is a concern, indicating potential heavy cash outlays or working capital shifts in that period.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company reported a net loss in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.24, while the forward-looking valuation can be inferred from the estimated revenue, suggesting the market is valuing the company at a significant discount to its sales. Compared to typical healthcare plan peers, a PS ratio below 0.25 is exceptionally low, often signaling deep value or significant fundamental concerns; this substantial discount likely reflects the market's punitive view on recent profitability challenges and uncertainty around Medicare rate environments. Historically, the stock's own PS ratio has fluctuated dramatically, from a high above 2.8 in 2022 to the current 0.24; trading near the absolute bottom of its historical valuation band suggests the market is pricing in a worst-case scenario, presenting a potential value opportunity if the company can stabilize earnings, but also carries the risk of a value trap if fundamentals continue to deteriorate.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Humana faces significant financial risks stemming from extreme earnings volatility and margin pressure. The Q4 2025 net loss of -$796 million and gross margin contraction to 11.67% demonstrate high sensitivity to medical cost trends and potential reserve adjustments. The company's tight liquidity, with a current ratio of 0.72, compounds this risk, limiting its buffer against further operational surprises. Furthermore, the negative free cash flow of -$1.85 billion in Q4, despite positive TTM figures, signals potential heavy periodic cash outlays that could strain the balance sheet if recurring.
Market & Competitive Risks: The primary market risk is that the recent valuation re-rating may be premature if profitability fails to recover, leaving the stock vulnerable to compression back towards its recent lows. While the PS ratio of 0.24 is deeply discounted, it reflects legitimate concerns that could resurface. The stock's fortunes remain heavily tied to government reimbursement rates for Medicare Advantage, making it susceptible to future regulatory changes. Although its beta of 0.68 suggests lower market correlation, the stock has proven highly volatile on company-specific news, as seen in the 47.54% drawdown earlier in the year.
Worst-Case Scenario: The worst-case scenario involves a recurrence of severe medical cost inflation or adverse regulatory developments that the recent CMS update failed to fully offset, leading to consecutive quarterly losses. This would trigger analyst downgrades, a loss of investor confidence in the turnaround narrative, and a flight from the stock. A realistic downside could see the price retracing a significant portion of its recent gains, potentially testing the $250-$275 support zone that preceded the late-January crash, representing a decline of approximately -25% to -30% from the current $349.80. A full return to the 52-week low of $163.11 seems less probable unless a fundamental crisis emerges, but a drawdown to the mid-$200s is a plausible adverse outcome.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: The company has shown extreme quarterly profit swings, most recently a -$796 million net loss in Q4 2025 after a profit in Q3. 2) Regulatory & Reimbursement Risk: Nearly all revenue is tied to government programs like Medicare, making it sensitive to payment rate changes from CMS. 3) Execution & Margin Risk: The company must prove it can manage medical costs effectively to convert the recent payment boost into sustained profits. 4) Liquidity & Cash Flow Risk: The negative free cash flow of -$1.85 billion in Q4 and a current ratio of 0.72 indicate potential near-term financial strain.
The 12-month forecast is bifurcated, with a high degree of uncertainty. Our analysis outlines three scenarios: a Bull Case (30% probability, target $380-$420) if profitability recovers strongly; a Base Case (50% probability, target $320-$360) if the stock consolidates recent gains amid choppy results; and a Bear Case (20% probability, target $250-$280) if earnings disappoint again. The Base Case is most likely, implying a range-bound stock as the market awaits more consistent proof of a turnaround. The key assumption behind this forecast is that the positive impact of the Medicare payment increase will be partially offset by ongoing medical cost pressures.
Based on traditional sales multiples, HUM appears significantly undervalued. Its trailing Price-to-Sales (PS) ratio of 0.24 is exceptionally low for a healthcare insurer and near the bottom of its historical range. However, this discount reflects the market's punitive view of its recent profitability challenges. The forward P/E of 22.3 is more in line with growth expectations. Therefore, the stock is fairly valued to slightly undervalued relative to its improved regulatory outlook but remains cheap on a sales basis due to embedded skepticism about earnings sustainability. The valuation implies the market expects only a modest recovery, not a rapid return to peak profitability.
HUM is a high-risk, high-potential-reward stock that may be suitable for certain investors. Following a 95% rally in three months driven by positive Medicare news, much of the near-term upside may be priced in. The stock trades at a deep valuation discount (PS ratio of 0.24), offering significant upside if profits recover, but the severe quarterly earnings volatility, including a Q4 net loss of -$796 million, presents a substantial downside risk. It could be a good buy for risk-tolerant investors seeking a turnaround play, but only on a pullback to stronger support levels (e.g., below $320) and with a long-term horizon to weather potential volatility.
HUM is more suitable for a medium- to long-term investment horizon (2+ years) rather than short-term trading. The company's turnaround narrative and the normalization of its valuation multiple will take multiple quarters to unfold, requiring patience. While the stock has high short-term volatility (as evidenced by its 47.54% drawdown and subsequent 95% rally), its low beta of 0.68 suggests it is less correlated with daily market moves over the long run. The lack of a significant dividend (yield 1.39%) further reduces its appeal for short-term income seekers. Investors should be prepared to hold through potential earnings-related volatility to realize the value proposition.